News

Ongoing toxicity studies of ChronVac-C delivered using Inovio’s electroporation-based system revealed that the combination induces a humoral response in rabbits that is comparable to results previously observed in

The phase III study is designed to evaluate the safety and efficacy of whole brain radiation therapy with increased oxygen. Efaproxyn increases the amount of oxygen in tumors

AzaSite is designed to treat bacterial conjunctivitis by enhancing the time the antibiotic spends on the surface of the eye. The application included clinical trials in which 698

The trial, named Study 07, was a randomized, double-blind, placebo-controlled study. The primary endpoint was the proportion of patients with at least a 50% improvement in the Brief

Financial terms of the transaction were not disclosed. However, Boehringer Ingelheim did reveal that IdeaSphere will take over the Pharmaton business and brands in their entirety. Both companies

BrainStorm, which focuses on treatments for neurodegenerative diseases, has previously demonstrated that its bone marrow stem cell technology can successfully differentiate adult stem cells into astrocyte-like cells with

If approved, guanfacine extended release (previously referred to as SPD503) would be the first once-daily selective alpha-2A-adrenoceptor agonist for the treatment of ADHD in children aged six to

The alliance aims to focus on novel medicines targeting four chemokine and chemoattractant receptors for the treatment of a variety of inflammatory disorders, including Traficet-EN, which is in

Bioxel’s paclitaxel active pharmaceutical ingredient (API) will be used by its client, which remains undisclosed, in generic drug product marketed primarily in Europe. This first order is valued